Promoting Patient-Centered Pharmacy Services through Effective Facility Planning and Design

2008 ◽  
Vol 43 (9) ◽  
pp. 762-768 ◽  
Author(s):  
Scott M. Mark ◽  
Thomas Kirschling ◽  
Robert J. Weber
2012 ◽  
Vol 174-177 ◽  
pp. 2205-2208
Author(s):  
Zhi Qing Zhao ◽  
Xiao Fei Kang

Along with the increasing development of Chinese urbanization, there have been a lot of cities facing the problem of old city renewal. However, during the process of re-plan and reconstruction of the old city, there is a series of changing that refers to the changing of land-use function, adjustment of land layout and the improvement of development intensity, which would change the load and setting of the urban infrastructures. Therefore, how to renew the municipal facilities safely and effectively to guarantee the routine life of people has become a crucial problem in the old city renewal. This paper takes the case study of Hengdaohezi town emphasizing the discussion on re-planning the municipal facilities in the process of old city renewal. Here, the author suggested that municipal facility planning should be carried out under the premise of safety and reliability. In the process of analysis, it should give consideration on the change of urban function and character as well, in order to make the municipal facility planning more scientific and reasonable providing support for the old city renewal from the perspective of municipal engineering.


2016 ◽  
Vol 51 (11) ◽  
pp. 944-949 ◽  
Author(s):  
Sandra Bai ◽  
John B. Hertig ◽  
Robert J. Weber

The changing landscape of health care mirrors that of health-system pharmacy, with pharmacists' scope of practice and provider status being the most significant changes. This creates new roles and opportunities; many of these roles are considered to be nontraditional in today's practice. This article reviews some new roles for pharmacy leaders that provide different career options and pathways. Nontraditional career opportunities discussed include expanded consulting roles in pricing analytics and drug pricing programs (contracting, 340B programs), pharmacogenomics patient consult services and clinics, specialty drug pharmacies, and compounding pharmacy services. To continue to develop high-performing pharmacy departments, pharmacy directors should recognize these roles and ensure they are clearly defined and managed. With the advent of these nontraditional opportunities, pharmacy departments can further expand their ability to provide advanced patient-centered pharmacy services.


2016 ◽  
Vol 30 (6) ◽  
pp. 612-620 ◽  
Author(s):  
Nicole P. Albanese ◽  
Alyssa M. Pignato ◽  
Scott V. Monte

Background: Despite the positive data on clinical outcomes, cost savings, and provider experience, no study has surveyed providers to evaluate what pharmacy services they find to be worthwhile. Objective: To determine what clinical, cost/access, and educational pharmacy services providers in a patient-centered medical home (PCMH) consider worthwhile and the perceived barriers to successful pharmacist incorporation. Methods: A cross-sectional online survey was distributed to primary care physicians, nurse practitioners, and physician assistants in a PCMH physician group. Results: The survey response rate was 78%. Top-tier clinical services were identified as medication counseling, reconciliation, adherence assessment, polypharmacy assessment, and drug information. Formulary review was the only top-tier cost- or access-related service. Top-tier educational services included new black-boxed warnings, drug market withdrawals, and new drug reviews. Ninety-one percent of providers were comfortable referring to a pharmacist for diabetes medication selection and dose titration, but no other disease state eclipsed 75%. More than twice as many providers found the pharmacy service to be very or extremely valuable when the pharmacist is physically located in the office versus virtual interactions (70% vs 34%). Conclusion: Top-tier clinical, cost/access, and educational services considered worthwhile by providers in a PCMH have been identified. In addition to these services, when developing or evaluating a pharmacy service, special attention should be paid to provider preference for physical location in the office and perceived barriers to the pharmacist availability, concern over complex disease management competency and patient confusion as to the role of the pharmacist.


2021 ◽  
Vol 17 (1) ◽  
pp. 1838-1844 ◽  
Author(s):  
Shabeer A. Thorakkattil ◽  
Habib S. Nemr ◽  
Fuad H. Al-Ghamdi ◽  
Rita J. Jabbour ◽  
Ayman M. Al-Qaaneh

2015 ◽  
Vol 30 (11) ◽  
pp. 664-670 ◽  
Author(s):  
Melanie McKain ◽  
Christine K. O'Neil

Author(s):  
Jürgen Gausemeier ◽  
Holger Krumm ◽  
Michael Grafe ◽  
Peter Ebbesmeyer

Abstract This paper provides an overview of the possibilities for using virtual reality technology in engineering applications. It concentrates on the planning and design of manufacturing processes and plants as well as facility planning. Modern design tools like simulation technology are introduced and it is discussed how these tools can be used in combination with virtual reality. Selected sample cases describe the benefits of using these technologies.


2017 ◽  
Vol 52 (2) ◽  
pp. 155-159 ◽  
Author(s):  
Kaitlyn N. Dana ◽  
John B. Hertig ◽  
Robert J. Weber

As spending on medications in the United States increases with each passing year, the need for drug pricing transparency by manufacturers also increases. Drug spending, excluding rebates and discounts, was $309.5 billion in 2015, up 8.5% from 2014. Drug pricing transparency has been a topic of debate across the health care system. This column reviews the issue of drug pricing and emphasizes the need for transparency in this area. We will discuss factors that influence drug pricing, policies and ways to reduce the rising costs of drugs, and the role of pharmacy leaders in managing this problem. A multitude of factors are driving the country to spend more and more on medications; pharmacy leaders can employ various strategies to counteract this escalation of drug prices. After reviewing this article, the pharmacy director will have an increased ability to address drug pricing issues with stakeholders as they develop patient-centered pharmacy services.


Sign in / Sign up

Export Citation Format

Share Document